Trial intelligence / Profile preview

Fruquintinib plus standard chemotherapy as second-line treatment after bevacizumab failure in advanced colorectal cancer

ChiCTR2300070163Phase 4Not yet recruiting

Sponsor

The Second Affiliated Hospital of Nanjing Medical University

Start

Apr 2023

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1